Repurposing itraconazole as a treatment for advanced prostate cancer: A noncomparative randomized phase ii trial in men with metastatic castration-resistant prostate cancer
Prostatic Neoplasms, Castration-Resistant
High-dose itraconazole (600 mg/day) has modest antitumor activity in men with metastatic CRPC that is not mediated by testosterone suppression.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency